212 related articles for article (PubMed ID: 3553893)
1. Studies on the ligand specificity and potential identity of microsomal antiestrogen-binding sites.
Watts CK; Sutherland RL
Mol Pharmacol; 1987 May; 31(5):541-51. PubMed ID: 3553893
[TBL] [Abstract][Full Text] [Related]
2. Antiestrogen binding in antiestrogen growth-resistant estrogen-responsive clonal variants of MCF-7 human breast cancer cells.
Miller MA; Lippman ME; Katzenellenbogen BS
Cancer Res; 1984 Nov; 44(11):5038-45. PubMed ID: 6488162
[TBL] [Abstract][Full Text] [Related]
3. Correlation of the antiproliferative action of diphenylmethane-derivative antiestrogen binding site ligands with antagonism of histamine binding but not of protein kinase C-mediated phosphorylation.
Brandes LJ; Gerrard JM; Bogdanovic RP; Lint DW; Reid RE; LaBella FS
Cancer Res; 1988 Jul; 48(14):3954-8. PubMed ID: 3164253
[TBL] [Abstract][Full Text] [Related]
4. Microsomal binding sites for antioestrogens in rat liver. Properties and detergent solubilization.
Watts CK; Sutherland RL
Biochem J; 1986 Jun; 236(3):903-11. PubMed ID: 3790095
[TBL] [Abstract][Full Text] [Related]
5. Resistance to tamoxifen with persisting sensitivity to estrogen: possible mediation by excessive antiestrogen binding site activity.
Pavlik EJ; Nelson K; Srinivasan S; Powell DE; Kenady DE; DePriest PD; Gallion HH; van Nagell JR
Cancer Res; 1992 Aug; 52(15):4106-12. PubMed ID: 1638522
[TBL] [Abstract][Full Text] [Related]
6. Structure-activity relationships of nonisomerizable derivatives of tamoxifen: importance of hydroxyl group and side chain positioning for biological activity.
Murphy CS; Parker CJ; McCague R; Jordan VC
Mol Pharmacol; 1991 Mar; 39(3):421-8. PubMed ID: 2005879
[TBL] [Abstract][Full Text] [Related]
7. Histamine and growth: interaction of antiestrogen binding site ligands with a novel histamine site that may be associated with calcium channels.
Brandes LJ; Bogdanovic RP; Cawker MD; LaBella FS
Cancer Res; 1987 Aug; 47(15):4025-31. PubMed ID: 2886214
[TBL] [Abstract][Full Text] [Related]
8. Antiestrogenic potency and binding characteristics of the triphenylethylene H1285 in MCF-7 human breast cancer cells.
Sheen YY; Ruh TS; Mangel WF; Katzenellenbogen BS
Cancer Res; 1985 Sep; 45(9):4192-9. PubMed ID: 4040807
[TBL] [Abstract][Full Text] [Related]
9. Antiestrogen pharmacology and mechanism of action.
Katzenellenbogen BS; Miller MA; Eckert RL; Sudo K
J Steroid Biochem; 1983 Jul; 19(1A):59-68. PubMed ID: 6887873
[TBL] [Abstract][Full Text] [Related]
10. Tamoxifen and metabolites in MCF7 cells: correlation between binding to estrogen receptor and inhibition of cell growth.
Coezy E; Borgna JL; Rochefort H
Cancer Res; 1982 Jan; 42(1):317-23. PubMed ID: 7053859
[TBL] [Abstract][Full Text] [Related]
11. Subcellular and extracellular localization of specific binding sites for triphenylethylene antiestrogens in human breast cancer.
Gulino A; Vacca A; Modesti A; Screpanti I; Farina A; Frati L
Biochem Pharmacol; 1986 Nov; 35(21):3863-70. PubMed ID: 3778510
[TBL] [Abstract][Full Text] [Related]
12. Antiestrogen binding sites in brain and pituitary of ovariectomized rats.
Gray JM; Ziemian L
Brain Res; 1992 Apr; 578(1-2):55-60. PubMed ID: 1511289
[TBL] [Abstract][Full Text] [Related]
13. An evaluation of the role of antiestrogen-binding sites in mediating the growth modulatory effects of antiestrogens: studies using t-butylphenoxyethyl diethylamine, a compound lacking affinity for the estrogen receptor.
Sheen YY; Simpson DM; Katzenellenbogen BS
Endocrinology; 1985 Aug; 117(2):561-4. PubMed ID: 4017947
[TBL] [Abstract][Full Text] [Related]
14. Synergy between tamoxifen and cisplatin in human melanoma cells is dependent on the presence of antiestrogen-binding sites.
Jones JA; Albright KD; Christen RD; Howell SB; McClay EF
Cancer Res; 1997 Jul; 57(13):2657-60. PubMed ID: 9205073
[TBL] [Abstract][Full Text] [Related]
15. Triphenylethylene antiestrogen-binding sites in cockerel liver nuclei: evidence for an endogenous ligand.
Murphy PR; Butts C; Lazier CB
Endocrinology; 1984 Jul; 115(1):420-6. PubMed ID: 6734522
[TBL] [Abstract][Full Text] [Related]
16. Antitumor activity of clomiphene analogs in vitro: relationship to affinity for the estrogen receptor and another high affinity antiestrogen-binding site.
Murphy LC; Sutherland RL
J Clin Endocrinol Metab; 1983 Aug; 57(2):373-9. PubMed ID: 6408114
[TBL] [Abstract][Full Text] [Related]
17. Steroidal affinity labels of the estrogen receptor. 3. Estradiol 11 beta-n-alkyl derivatives bearing a terminal electrophilic group: antiestrogenic and cytotoxic properties.
Lobaccaro C; Pons JF; Duchesne MJ; Auzou G; Pons M; Nique F; Teutsch G; Borgna JL
J Med Chem; 1997 Jul; 40(14):2217-27. PubMed ID: 9216841
[TBL] [Abstract][Full Text] [Related]
18. Antiestrogen binding site and estrogen receptor mediate uptake and distribution of 4-hydroxytamoxifen-targeted doxorubicin-formaldehyde conjugate in breast cancer cells.
Burke PJ; Kalet BT; Koch TH
J Med Chem; 2004 Dec; 47(26):6509-18. PubMed ID: 15588086
[TBL] [Abstract][Full Text] [Related]
19. Comparative affinity of steroidal and non-steroidal antioestrogens, cholesterol derivatives and compounds with a dialkylamino side chain for the rat liver antioestrogen binding site.
van den Koedijk CD; Vis van Heemst C; Elsendoorn GM; Thijssen JH; Blankenstein MA
Biochem Pharmacol; 1992 Jun; 43(12):2511-8. PubMed ID: 1632810
[TBL] [Abstract][Full Text] [Related]
20. Modifications of benzylphenoxy ethanamine antiestrogen molecules: influence affinity for antiestrogen binding site (AEBS) and cell cytotoxicity.
Delarue F; Kedjouar B; Mésange F; Bayard F; Faye JC; Poirot M
Biochem Pharmacol; 1999 Mar; 57(6):657-61. PubMed ID: 10037451
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
